One such class of medications that has shown considerable promise in treating diabetes is incretin-based pharmacotherapies, including glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, plus or minus glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs). The gene discussed is GIP; the disease is diabetes mellitus.